What Kymanox does

Kymanox Corporation is a life sciences professional services firm founded in 2004 and headquartered in Morrisville, North Carolina. The company provides integrated engineering, scientific, regulatory, compliance, and project management consulting services to pharmaceutical, biotechnology, medical device, and combination product developers. Kymanox organizes its work around five core focus areas — Combination Products, Biologics & Advanced Therapies, Design/Development/Testing, Facilities & Manufacturing Services, and Quality & Compliance — with deeper sub-services spanning CMC, human factors engineering, sterilization engineering, validation (CQV), analytical sciences, drug delivery device design, and regulatory affairs. The company claims 4,000+ projects completed in the past year and a 100% success rate in client regulatory inspections (PAI, PLI).

The firm operates without a proprietary technology platform and monetizes through project-based engagements and retainer arrangements with enterprise clients. Go-to-market is direct enterprise sales supported by a thought-leadership engine: a website with regular blog content, a 10,000+-subscriber newsletter, the Life Science Solutions podcast, an extensive case-study library, and active participation in industry conferences (PDA/FDA Joint Regulatory Conference, DDF Summit, PDA Universe). Delivery is supported by offices in Morrisville NC, King of Prussia PA, Bern, and Munich, and an emerging Hyper-Virtual Model for remote engagements.

Since a 2021 growth recapitalization by WestView Capital Partners, Kymanox has executed four acquisitions — Neuma (August 2021, drug delivery services), Anteris Medical GmbH and Anteris Helvetia AG (February 2023, European expansion), Agilis Consulting Group (March 2023, regulatory strategy and human factors), and an earlier 2014 Freedom Labs deal — building a multi-brand life sciences services platform across the US and EU. The company is privately held and operates as a portfolio company under WestView's sponsorship with debt facilities arranged by Abacus Finance Group.

Name

Kymanox

Legal name

Kymanox Corporation

Website

https://kymanox.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

251–500 employees

Short description

Kymanox is a life sciences professional services firm providing integrated engineering, regulatory, quality, and project management consulting to pharmaceutical, biotechnology, medical device, and combination product companies across the US and Europe.

Ownership category

akta.pro rank

Headquarters

HQ city

Morrisville

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Professional Services: Kymanox generates revenue through consulting and professional services engagements, providing specialized expertise in regulatory strategy, quality and compliance, design and development, facilities and manufacturing services, and project management for life sciences clients. Services are delivered through project-based engagements and retainer arrangements with pharmaceutical, biotech, medical device, and combination product companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Kymanox is a life sciences professional services firm that provides integrated engineering, scientific, regulatory, quality, and project management support to biotechnology, pharmaceutical, medical device, and combination product companies. Services span the product lifecycle from development through commercialization, delivered via project-based consulting engagements and retainer arrangements, with sub-offerings covering combination products, biologics & advanced therapies, design/development/testing, facilities & manufacturing services, and quality & compliance.

Product overview

Kymanox is a life sciences professional services company offering integrated consulting services across five core areas: Combination Products, Biologics & Advanced Therapies, Design/Development & Testing, Facilities & Manufacturing Services, and Quality & Compliance. The company operates as a unified platform with specialized sub-services including Clinical Affairs, CMC, Human Factors Engineering, Sterilization Engineering, Validation (CQV), Quality Management Systems, Project Management, Analytical Sciences, Drug Delivery Device Design, and Regulatory Affairs. Additional offerings include the Kymanox Executive Advisors (KEA) sub-brand for strategic consulting and a Hyper-Virtual Model for remote service delivery. The company also produces the Life Science Solutions podcast as thought leadership content. Kymanox supports biotechnology, pharmaceutical, medical device, and combination product companies throughout the product lifecycle from clinic to commercial.

Differentiator

Problem solved

Functional benefit

Brands

• Kymanox Executive Advisors: Executive advisory services offered by Kymanox to support life science industry clients

Products and services

• Combination Products Services Integrated drug-device consulting offering covering CMC/Pharma Science, Product & Device Development, Manufacturing Science & Technology, Clinical Affairs, Human Factors Engineering, Regulatory Affairs, Strategic Support, and Project Management for combination product developers.
• Biologics & Advanced Therapies Services Expert-driven consulting solutions for biotechnology companies covering CMC/Pharma Science, Process Engineering, Regulatory Affairs & Quality Assurance, Supply Chain & Logistics, and Digital Solutions, focused on monoclonal antibodies and advanced therapies.
• Design, Development, and Testing Services Human-centered design, robust testing, and engineering consulting covering Design & Innovation, Product & Device Development, Test Engineering, Human Factors Engineering, Sterilization Engineering, and Quality Assurance for medical devices and combination products.
• Facilities & Manufacturing Services Operational readiness and scalable consulting solutions spanning Facility & Utility Engineering, Automation, Validation (CQV), Computer System Validation, Quality Assurance, Analytical Sciences, Process Engineering & Technology Transfer, and Project Management for life sciences manufacturers.
• Quality & Compliance Services Consulting services ensuring safety, efficacy, and compliance, including Quality Leadership, Quality & Event Management, Audits & Inspection Readiness, Quality Engineering, and Regulatory Affairs for life sciences clients.
• Ancillary Support Services Supplementary consulting offerings including Regulatory Affairs, Executive Strategy, and Project Management, delivered through alternative business models such as the Emerging Enterprise and Hyper Virtual Model.
• Kymanox Executive Advisors (KEA) Executive strategy consulting sub-brand offering senior advisory support to life science organizations.
• Hyper-Virtual Model Virtual consulting delivery model enabling remote life science consulting services for clients requiring distributed engagement.

Quantifiable outcome

• 4,000+ projects completed in the last year
• +2 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core.

• Agilis Consulting GroupcoreStrategic or Co-development PartnerKymanox acquired Agilis Consulting Group in March 2023 to expand its service capabilities in regulatory strategy and human factors for life sciences clients. The acquisition enhances the companies' ability to support bringing new medicines, biologics, and medical devices to market.
• Anteris Medical GmbH and Anteris Helvetia AGcoreStrategic or Co-development PartnerKymanox acquired Anteris Medical GmbH (Germany) and Anteris Helvetia AG (Switzerland) in February 2023 to expand capabilities and geographic reach within the life science industry. The acquisition enhances services related to development and commercialization of medical devices, combination products, and biologics.
• NeumacoreStrategic or Co-development PartnerKymanox acquired Neuma, a drug delivery services provider based in Pennsylvania in August 2021, to expand its capabilities in medical device technologies and support early-stage programs. The deal followed Kymanox's growth capital investment from WestView Capital Partners.

Scale indicators4 records

Recent moves5 records

Expansion highlights6 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@kymanox
• LinkedInlinkedin.com/company/kymanox
• Xx.com/kymanox

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries4 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kymanox